Wellbutrin (Bupropion)
bupropion hydrochloride tablets (IR, SR, XL formulations)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Major Depressive Disorder (MDD) | Adults | Monotherapy or adjunctive | FDA Approved |
| Seasonal Affective Disorder (SAD) prevention | Adults | Monotherapy (XL only) | FDA Approved |
| Smoking cessation aid | Adults | Monotherapy or with NRT (as Zyban SR) | FDA Approved |
Bupropion is the only marketed norepinephrine-dopamine reuptake inhibitor (NDRI) and occupies a unique position among antidepressants. First approved in 1985, it is now available in three oral formulations: immediate-release (IR, three times daily), sustained-release (SR, twice daily), and extended-release (XL, once daily). Its efficacy for MDD was established in controlled inpatient and outpatient trials using the IR formulation, with the SR and XL formulations demonstrating bioequivalence. The XL formulation additionally holds an indication for the prevention of seasonal major depressive episodes. Bupropion is also marketed as Zyban (SR) for smoking cessation and is a component of the combination product Contrave (naltrexone/bupropion) for chronic weight management. Bupropion is distinguished from SSRIs and SNRIs by its lack of serotonergic activity, resulting in markedly lower rates of sexual dysfunction, weight gain, and sedation.
SSRI/SNRI-induced sexual dysfunction (augmentation): Widely used as adjunctive therapy to counteract antidepressant-related sexual side effects. Supported by clinical trial data and guideline recommendations. Evidence quality: Moderate.
Adult ADHD: Multiple controlled trials show benefit, particularly in patients who cannot tolerate stimulants. Recommended in some guidelines as a second-line option. Evidence quality: Moderate.
Obesity/weight management: Approved as combination product (naltrexone/bupropion); used off-label as monotherapy. AGA guidelines support use. Evidence quality: Moderate (combination); Low (monotherapy).
Bipolar depression (adjunctive with mood stabilizer): Used cautiously alongside mood stabilizers; evidence suggests lower switch risk than SSRIs. Evidence quality: Low.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| MDD — XL formulation (preferred) | 150 mg once daily (morning) | 300 mg once daily | 300 mg/day (standard); 450 mg/day (Forfivo XL) | Increase to 300 mg after 4 days if tolerated 300 mg is the recommended target; 450 mg (Forfivo XL) available for patients requiring higher dose after adequate trial at 300 mg. Seizure risk increases above 300 mg. |
| MDD — SR formulation | 150 mg once daily (morning) | 150 mg twice daily | 400 mg/day (200 mg BID) | Increase to 150 mg BID after 3 days; doses ≥8 h apart Do not exceed 200 mg in any single dose |
| MDD — IR formulation | 100 mg twice daily | 100 mg three times daily | 450 mg/day (150 mg TID) | After 3 days increase to TID; doses ≥6 h apart Do not exceed 150 mg in any single dose; most complex regimen |
| SAD prevention — XL formulation | 150 mg once daily | 300 mg once daily | 300 mg/day | Initiate in autumn before symptom onset; increase after 7 days Continue through winter; taper to 150 mg/day before discontinuing in early spring |
| Smoking cessation — SR (Zyban) | 150 mg once daily × 3 days | 150 mg twice daily | 300 mg/day | Start 1–2 weeks before target quit date; treat for 7–12 weeks Can combine with NRT; do not use with other bupropion products |
| Moderate-severe hepatic impairment (Child-Pugh 7–15) | XL: 150 mg every other day | SR: 100 mg/day or 150 mg QOD | 150 mg QOD (XL) or 100 mg/day (SR) | Markedly reduced clearance; bupropion and metabolites accumulate | |
| Mild hepatic impairment (Child-Pugh 5–6) | Consider reducing dose and/or frequency | Monitor closely for adverse effects | ||
| Renal impairment (GFR <90 mL/min) | Consider reducing dose and/or frequency | Active metabolites (hydroxybupropion, threohydrobupropion) may accumulate No specific dosing guidelines; use clinical judgment | ||
The XL formulation is generally preferred for MDD due to once-daily dosing, which improves adherence, and lower evening plasma concentrations, which may reduce insomnia risk. The SR formulation offers dosing flexibility (100, 150, 200 mg tablets) and is the formulation approved for smoking cessation (as Zyban). The IR formulation is rarely used first-line due to the need for three-times-daily dosing and higher peak concentrations. All formulations are bioequivalent at the same total daily dose. Patients must not combine different bupropion products (e.g., Wellbutrin XL plus Zyban), as this increases seizure risk.
Bupropion carries a dose-dependent seizure risk that distinguishes it from all other modern antidepressants. At doses up to 300 mg/day (SR), the incidence is approximately 0.1% (1 in 1000). At 300–450 mg/day (IR), it is approximately 0.4% (4 in 1000). Between 450–600 mg/day, the risk increases almost tenfold. To minimize seizure risk: (1) never exceed the maximum recommended dose for the formulation, (2) titrate gradually, (3) never exceed 200 mg (SR) or 150 mg (IR) in any single dose, and (4) screen for predisposing factors before initiation.
Pharmacology
Mechanism of Action
Bupropion is an aminoketone antidepressant that inhibits the reuptake of norepinephrine and dopamine (NDRI). Unlike SSRIs and SNRIs, bupropion has no clinically meaningful serotonergic activity, which explains its distinctly different side-effect profile: minimal sexual dysfunction, no weight gain, and no sedation. It also acts as a non-competitive antagonist at nicotinic acetylcholine receptors, which contributes to its efficacy in smoking cessation. Bupropion is a racemic mixture, and the pharmacological activity of individual enantiomers has not been fully characterized. The drug undergoes extensive metabolism to three active metabolites, of which hydroxybupropion is the most pharmacologically relevant, reaching steady-state plasma concentrations approximately 17 times those of the parent compound.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Well absorbed orally; extensive first-pass metabolism; Tmax: IR ~2 h, SR ~3 h, XL ~5 h; food increases Cmax by 11–35% (SR) without clinically significant effect | Can be given with or without food; XL formulation provides lower peak concentrations and reduced insomnia risk; steady state in ~8 days |
| Distribution | Protein binding 84%; widely distributed | Moderate protein binding; tissue distribution supports CNS penetration |
| Metabolism | Primary: CYP2B6 (to hydroxybupropion); also non-CYP pathways (to threohydrobupropion and erythrohydrobupropion); hydroxybupropion AUC ~17x parent at steady state | CYP2B6 inducers (ritonavir, efavirenz, carbamazepine) can decrease bupropion exposure; bupropion and metabolites are CYP2D6 inhibitors (clinically significant DDI) |
| Elimination | t½: ~21 h (bupropion, chronic); ~20 h (hydroxybupropion); ~33 h (erythrohydrobupropion); ~37 h (threohydrobupropion); 87% urine (0.5% unchanged), 10% feces | Long metabolite half-lives mean accumulation over days; renal impairment causes metabolite accumulation; hepatic impairment markedly reduces bupropion clearance |
Side Effects
| Adverse Effect | Incidence (300 mg SR) | Clinical Note |
|---|---|---|
| Headache | 26% (placebo 23%) | Only ~3% excess over placebo; common but largely background rate; often improves with continued treatment; responds to OTC analgesics |
| Dry mouth | 17% (placebo 7%) | Dose-related (24% at 400 mg); encourage hydration, sugar-free gum, oral hygiene |
| Nausea | 13% (placebo 8%) | Usually transient; dose-related (18% at 400 mg); taking with food may help |
| Insomnia | 11% (placebo 6%) | Dose-dependent; minimize by taking last dose early; XL formulation may reduce this compared to SR |
| Constipation | 10% (placebo 7%) | Increase fiber and fluid intake; osmotic laxative if persistent |
| Adverse Effect | Incidence (300 mg SR) | Clinical Note |
|---|---|---|
| Dizziness | 7% (placebo 5%) | Usually transient and mild |
| Tremor | 6% (placebo 1%) | Fine postural tremor; dose-related; more prominent at 400 mg |
| Sweating | 6% (placebo 2%) | Noradrenergic/dopaminergic mediated; use antiperspirants |
| Tinnitus | 6% (placebo 2%) | Usually mild; dose-related; monitor and reduce dose if persistent |
| Anxiety | 5% (placebo 3%) | Activating properties may worsen anxiety in predisposed patients; consider dose reduction |
| Anorexia / decreased appetite | 5% (placebo 2%) | Dose-related weight loss occurs; 28% lose ≥5 lbs at 300 mg (vs 15% placebo in SR trials) |
| Rash | 5% (placebo 1%) | Cause of discontinuation in ≥1% of patients; evaluate for hypersensitivity reaction |
| Agitation | 3% (placebo 2%) | Related to activating/dopaminergic properties; more prominent at 400 mg (9%) |
| Abdominal pain | 3% (placebo 2%) | More common at higher doses (9% at 400 mg) |
| Pharyngitis | 3% (placebo 2%) | Likely related to dry mouth; ensure adequate hydration |
| Palpitation | 2% (placebo 2%) | More common at 400 mg (6%); evaluate if persistent |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Seizures | ~0.1% at ≤300 mg SR; ~0.4% at 300–450 mg IR | Any time; dose-dependent | Discontinue permanently; never rechallenge; contraindicated in seizure disorders, eating disorders, alcohol/benzo withdrawal |
| Suicidal ideation (age <25) | Uncommon | First weeks or dose changes | Close monitoring; FDA Black Box Warning |
| Hypertension | Uncommon | Weeks to months | Monitor BP before and during treatment; consider dose reduction or discontinuation |
| Anaphylaxis / Stevens-Johnson syndrome | Rare | Variable | Discontinue immediately; emergency care; contraindication to rechallenge |
| Mania / hypomania activation | Uncommon | First weeks | Screen for bipolar before initiation; discontinue; initiate mood stabilizer |
| Psychosis, hallucinations, paranoia | Rare | Variable | Discontinue; psychiatric evaluation; reported particularly in smoking cessation context |
| Hepatotoxicity | Rare | Variable | Discontinue if liver function tests significantly elevated or if jaundice develops |
| Angle-closure glaucoma | Rare | Any time | Avoid in untreated anatomically narrow angles; urgent ophthalmology referral |
Bupropion stands apart from all other marketed antidepressants in two clinically important areas. Sexual dysfunction rates are comparable to placebo (<1% in clinical trials), making it the preferred antidepressant when sexual side effects are a primary concern. Weight change is neutral to negative: a dose-related weight loss was observed across all trials, and in SAD trials 23% of patients on bupropion XL lost ≥5 lbs compared to 11% on placebo. This profile makes bupropion particularly suitable for patients with fatigue-predominant depression, hypersomnia, or for augmenting SSRIs/SNRIs when sexual dysfunction or weight gain limits adherence.
Drug Interactions
Bupropion has a clinically significant drug interaction profile driven by two main mechanisms: (1) its metabolism via CYP2B6 makes it susceptible to enzyme inducers, and (2) bupropion and its metabolites are moderate CYP2D6 inhibitors, which can raise concentrations of many co-administered drugs. Unlike SSRIs/SNRIs, bupropion does not carry serotonin syndrome risk (it is not serotonergic), but its MAOI interaction involves hypertensive reactions rather than serotonin toxicity. It also causes false-positive urine drug screens for amphetamines.
Monitoring
- Blood PressureBaseline, then periodically
RoutineBupropion can increase blood pressure, sometimes severely. Monitor before initiation and periodically during treatment. Risk is increased when combined with MAOIs or drugs that increase dopaminergic/noradrenergic activity. - Suicidality AssessmentWeekly for first 4 weeks, then at each visit
RoutineEspecially important in patients under 25. Monitor for clinical worsening, agitation, irritability, and suicidal ideation. - Seizure Risk AssessmentBaseline
RoutineScreen for predisposing factors before initiation: seizure history, eating disorders, alcohol/benzo dependence, head injury, CNS tumors, metabolic disorders. Reassess if dose is increased or concomitant medications change. - WeightBaseline, then periodically
RoutineA dose-related decrease in body weight occurs. Consider the anorectic/weight-reducing potential if weight loss is a presenting feature of the patient’s depression. - Hepatic FunctionBaseline; as indicated
Trigger-basedBupropion undergoes extensive hepatic metabolism. Hepatic impairment markedly increases exposure. Monitor LFTs if symptoms of hepatotoxicity develop (jaundice, dark urine, upper abdominal pain). - Renal FunctionBaseline
RoutineActive metabolites are renally excreted and may accumulate in renal impairment. Consider reduced dose/frequency if GFR <90 mL/min. - Neuropsychiatric SymptomsEach visit
RoutineMonitor for psychosis, hallucinations, paranoia, agitation, hostility, particularly in patients using bupropion for smoking cessation (FDA warning). Also screen for bipolar symptoms.
Contraindications & Cautions
Absolute Contraindications
- Seizure disorder (any current seizure disorder)
- Current or prior diagnosis of bulimia or anorexia nervosa (higher seizure incidence observed)
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs (increased seizure risk)
- Concurrent MAOI use or use within 14 days of MAOI discontinuation in either direction (hypertensive crisis risk)
- Concurrent linezolid or IV methylene blue (reversible MAO inhibition)
- Known hypersensitivity to bupropion or any excipient (anaphylaxis, Stevens-Johnson syndrome reported)
- Concurrent use of other bupropion-containing products (Zyban, Contrave, Forfivo XL) due to additive seizure risk
Relative Contraindications (Specialist Input Recommended)
- Conditions that lower seizure threshold: Severe head injury, AV malformation, CNS tumors, CNS infections, severe stroke, metabolic disorders (hypoglycemia, hyponatremia, hypoxia)
- Excessive alcohol use (without abrupt cessation): Increases seizure risk; minimize or avoid alcohol
- Diabetes treated with hypoglycemic agents or insulin: Hypoglycemia may lower seizure threshold
- Severe hepatic impairment: Markedly reduced clearance necessitates strict dose limitation
Use with Caution
- Renal impairment: Metabolite accumulation; reduce dose/frequency
- Mild hepatic impairment: Consider reducing dose/frequency
- Bipolar disorder: Screen before initiation; may precipitate mania
- Patients receiving concomitant drugs that lower seizure threshold
- Elderly patients: No specific dose adjustment, but consider renal/hepatic function
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (18–24) in short-term studies. Adults over 24 did not show increased risk; adults 65+ showed reduced risk. Monitor all patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the first months and at dose changes. Bupropion is not approved for pediatric use.
Bupropion can cause false-positive urine immunoassay results for amphetamines. This is a recognized cross-reactivity issue, not an indication of amphetamine use. Confirmatory testing with gas chromatography/mass spectrometry (GC/MS) will distinguish bupropion from true amphetamine positives. Clinicians should document bupropion prescriptions and inform patients of this possibility to prevent adverse legal or employment consequences.
Patient Counselling
Purpose of Therapy
Bupropion is prescribed to treat depression by increasing the availability of norepinephrine and dopamine in the brain. Unlike many other antidepressants, it is less likely to cause sexual side effects or weight gain. Improvement in mood and energy typically begins within 1 to 2 weeks, with full effect over 4 to 6 weeks. It is important to continue taking the medication as prescribed even after symptoms improve.
How to Take
Take the medication at approximately the same time each day, preferably in the morning to minimize insomnia. Swallow tablets whole; do not crush, chew, or divide extended-release or sustained-release tablets, as this can release the drug too quickly and increase side effects, including seizure risk. If you notice an inert tablet shell in your stool with the XL formulation, this is normal and means the active medication has already been absorbed.
Sources
- Wellbutrin XL (bupropion hydrochloride extended-release) Tablets. Full Prescribing Information. Bausch Health US, LLC. Revised March 2024. accessdata.fda.govPrimary source for XL dosing, MDD and SAD indications, contraindications, seizure data, and adverse reaction rates.
- Wellbutrin SR (bupropion hydrochloride sustained-release) Tablets. Full Prescribing Information. GlaxoSmithKline. Revised April 2024. accessdata.fda.govPrimary source for SR adverse reaction Table 3 data, discontinuation rates, and PK parameters used in this monograph.
- Wellbutrin (bupropion hydrochloride) Tablets. Full Prescribing Information. accessdata.fda.govReference for IR formulation PK parameters, half-life data, and original efficacy trials.
- Modell JG, Rosenthal NE, Harriett AE, et al. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry. 2005;58(8):658-667. doi:10.1016/j.biopsych.2005.07.021Pivotal SAD prevention trial supporting the XL formulation’s unique seasonal indication.
- Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005;66(8):974-981. doi:10.4088/JCP.v66n0803Meta-analysis demonstrating comparable efficacy of bupropion SR vs SSRIs for MDD with superior sexual function tolerability.
- Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Can J Psychiatry. 2024;69(9):641-687. doi:10.1177/07067437241245384Current guideline recommending bupropion as a first-line antidepressant, particularly when sexual dysfunction or weight gain are concerns.
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. APA; 2010. psychiatryonline.orgAPA guideline including bupropion as a first-line option for MDD and as augmentation strategy.
- Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166. doi:10.4088/PCC.v06n0403Comprehensive review of bupropion’s NDRI mechanism, nicotinic antagonism, and relationship between pharmacology and clinical effects.
- Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7(3):106-113. doi:10.4088/PCC.v07n0305Authoritative overview of 15 years of clinical data across all formulations, including comparative PK, adverse event profiles, and clinical advantages.
- Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther. 2005;27(11):1685-1695. doi:10.1016/j.clinthera.2005.11.011Detailed pharmacokinetic comparison of IR, SR, and XL formulations including metabolite profiles and steady-state exposure data.
- Bupropion. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. ncbi.nlm.nih.govCurrent comprehensive review of clinical applications, mechanism of action, dosing, adverse effects, and toxicity across all formulations and indications.
- Berigan TR. The many uses of bupropion and bupropion sustained release (SR) in adults. Prim Care Companion J Clin Psychiatry. 2002;4(1):30-32. doi:10.4088/PCC.v04n0110Review of off-label applications including ADHD, bipolar depression, SSRI-induced sexual dysfunction, and weight management.